Ultimately the plan will be judged by its real-world impact on health outcomes. At this years’ OHE Annual Lecture in September, Professor Anita Charlesworth will offer reflections on the economic ...

The Change Initiative Prevention Programme, delivered in partnership with leading global actors, aims to reframe prevention ...

In this report, we investigate the theory and practice of value-based pricing in the pharmaceuticals industry, and provide recommendations for how implementation of value-based pricing can be enhanced ...

Earlier today, the UK government unveiled the long-awaited NHS Ten Year Plan. Commenting on the Plan, Professor Graham Cookson, Chief Executive of the Office of Health Economics, said: “The hotly ...

This report contributes to the understanding of people’s proximity to dementia (e.g., people with dementia and their carers forecast) and so the potential future number of people who will be impacted ...

Real-World Evidence (RWE) can provide decision-makers in the healthcare sector with insights into the functioning of health technologies outside of clinical trial settings. In this report, we focus on ...

Most value assessments of vaccination programs are carried out by taking the perspective of the health system. To stimulate the debate concerning the broader value of vaccination beyond this ...

In this report, we propose a novel payment model that will incentivise broader value demonstration for diagnostics for antibiotics that could inform longer-term financing and reimbursement ...

The report highlights the burden of Hidradenitis Suppurativa (HS) on patients, the NHS and society and makes recommendations to improve life for people living with HS and lessen the burden on the NHS ...

In this report, we describe the design of a globally aligned, value-based, fully-delinked pull incentive, where payers provide manufacturers with a pre-specified subscription fee based on the value of ...

It’s not often that you witness a health system reinvent itself in real-time. And yet, this is precisely what is happening across the Middle East.

This is the second in our series of Insights considering the implications of President Trump’s Executive Order on ‘Most Favoured Nation’ drug pricing. We know that pegging US drug prices to the rest ...